Bibliographic
Application Type
Invention
Application SubType
Invention PCT
(10) Registration Number and Date
Status
893/${sta2}
(180) Expiration Date
(20) Filing Number and Date
PH 1/2024/552189 2023.03.17
(40) Publication Number and Date
PH 1/2024/552189
U3
2025.02.10
(86) PCT Filing Number and Date
PCT/IB2023/052613 2023.03.17
(87) PCT Publication Number and Date
IB WO/2023/175573 2023.09.21
(85) National Entry Date
(30) Priority Details
IN 202221014813
2022.03.17
(51) IPC Classes
(71/73) Applicant
(72) Inventor
(EN) BODIWALA, Hardik Satish : ZYDUS LIFESCIENCES LIMITED Zydus Corporate Park Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle Sarkhej- Gandhinagar Highway, Ahmedabad, Gujarat
(EN) JOGANI, Pranav Dhirajbhai : ZYDUS LIFESCIENCES LIMITED Block Number 2-5, Sigma Commerce Zone, Near Iscon Cross Roads, Ambli-Bopal Road, Ahmedabad Gujarat
(EN) MITTAL, Ravindra : ZYDUS LIFESCIENCES LIMITED Zydus Corporate Park Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle Sarkhej- Gandhinagar Highway, Ahmedabad, Gujarat
(EN) SHAH, Nilay Yagnesh : ZYDUS LIFESCIENCES LIMITED Block Number 2-5, Sigma Commerce Zone, Near Iscon Cross Roads, Ambli-Bopal Road, Ahmedabad Gujarat
(EN) UPADHYAY, Vinay Satishchandra : ZYDUS LIFESCIENCES LIMITED Block Number 2-5, Sigma Commerce Zone, Near Iscon Cross Roads, Ambli-Bopal Road, Ahmedabad Gujarat
(EN) VAISHNANI, Rohit Girdharlal : ZYDUS LIFESCIENCES LIMITED Block Number 2-5, Sigma Commerce Zone, Near Iscon Cross Roads, Ambli-Bopal Road, Ahmedabad Gujarat
(74) Representative Name
(EN) ANGARA ABELLO CONCEPCION REGALA AND CRUZ Law Office : 22nd Floor ACCRALAW Tower, Second Aveñue corner 30th Street, Crescent Park West, Bonifacio Global City
(54) Title
(EN) PHARMACEUTICAL COMPOSITIONS COMPRISING A ß-BLOCKER AND AN SGLT2 INHIBITOR
(57) Abstract
(EN)

The invention relates to once-a-day pharmaceutical compositions comprising a fixed dose combination of a β-blocker or a pharmaceutically acceptable salt or ester thereof and an SGLT2 inhibitor or a pharmaceutically acceptable salt or ester thereof with one or more pharmaceutically acceptable excipients. In addition, the present invention also relates to use of such pharmaceutical compositions in patients for the prevention or treatment of heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, angina, myocardial infarction, arteriosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, and chronic heart failure.

(58) Citations
Document
Document Type Date Action
Event
Event NameDateStatus
Filing2023.03.17Filed
PCT National Phase Entry2024.09.16PCT National Phase
Publication2025.02.10PUBLISHED
-2025.02.10893
Description
Claims